L-Acetylcarnitine: A proposed therapeutic agent for painful peripheral neuropathies

Current Neuropharmacology

Volumn 4, Issue 3, 2006, Pages 233-237

  Chiechio, S ^a   Copani, A ^b   Nicoletti, F ^c,d   Gereau IV, Robert W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Antinociception; L acetylcarnitine; Neuropathic pain; Peripheral neuropathies

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CISPLATIN; DIDANOSINE; LEVACECARNINE; LOCAL ANESTHETIC AGENT; OPIATE DERIVATIVE; PACLITAXEL; PLACEBO; SODIUM CHANNEL BLOCKING AGENT; TOPICAL AGENT; VINCRISTINE; ZIDOVUDINE;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSESTHESIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; HYPERESTHESIA; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; NERVE INJURY; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; PARESTHESIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; SENSORY NEUROPATHY; SPINAL CORD DISEASE; SPINAL CORD INJURY; STROKE; SYMPTOMATOLOGY; SYRINGOMYELIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33747270685     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015906778019509     Document Type: Review

References (56)

1. Angelucci, L., Ramacci, M.T., Taglialatela, G., Hulsebosch, C., Morgan, B., Werrbach-Perez, K., Perez-Polo, R. (1988) Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J. Neurosci. Res., 20, 491-6.
2. Berger, A., Dukes, E.M., Oster, G. (2004) Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain, 5, 143-9.
3. Bremer, J. (1983) Carnitine--metabolism and functions. Physiol. Rev., 63, 1420-80.
4. Bremer, J. The role of carnitine in intracellular metabolism. (1990) J. Clin. Chem. Clin. Biochem., 28, 297-301.
5. Brew, B.J. (1994) The clinical spectrum and pathogenesis of HIV encephalopathy, myelopathy, and peripheral neuropathy. Curr. Opin. Neurol., 7, 209-16.
6. Brunner, S., Kramar, K., Denhardt, D.T., Hofbauer, R. (1997) Cloning and characterization of murine carnitine acetyltransferase: evidence for a requirement during cell cycle progression. Biochem. J., 322, 403-10.
7. Chiechio, S., Caricasole, A., Barletta, E., Storto, M., Catania, M.V., Copani, A., Vertechy, M., Nicolai, R., Calvani, M., Melchiorri, D., Nicoletti, F. (2002) L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol. Pharmacol., 61, 989-96.
8. Chiechio, S., Copani, A., Melchiorri, D., Canudas, A.M., Storto, M., Calvani, M., Nicolai, R., Nicoletti, F. (2004) Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain. J. Endocrinol. Invest., 27, 171-6.
9. De Grandis, D., Minardi, C. (2002) Acetyl-L-carnitine (levace-carnine) in the treatment of diabetic neumpathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D, 3, 223-31.
10. De Simone, R., Ramacci, M.T., Aloe, L. (1991) Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats. Int. J. Dev. Neurosci., 9, 39-46.
11. Duggan, A.W., Hope, P.J., Jarrott, B., Schaible, H.G., Fleetwood-Walker, S.M. (1990) Release, spread and persistence of immunoreactive neurokinin A in the dorsal horn of the cat following noxious cutaneous stimulation. Studies with antibody microprobes. Neuroscience, 35, 195-202.
12. Eisenberg, E., McNicol, E.D., Carr, D.B. (2005) Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA, 293, 3043-52.
13. Famularo, G., Moretti, S, Marcellini, S., Trinchieri, V., Tzantzoglou, S., Santini, G., Longo, A., De Simone, C. (1997) Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS, 11, 185-90.
14. Galeotti, N., Bartolini, A., Calvari, M., Nicolai, R., Ghelardini, C. (2004) Acetyl-L-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology, 47, 286-94.
15. Ghelardini, C., Galeotti, N., Calvani, M., Mosconi, L., Nicolai, R., Bartolini, A. (2002) Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology, 43, 1180-7.
16. Ghirardi, O., Lo Giudice, P., Pisano, C., Vertechy, M., Bellucci, A., Vesci, L., Cundari, S., Mieloso, M., Rigamonti, L.M., Nicolini, G., Zanna, C., Carminati, P. (2005) Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res., 25, 2681-7.
17. Ghirardi, O., Vertechy, M., Vesci, L., Canta, A., Nicolini, G., Galbiati, S., Ciogli, C., Quattrini, G., Pisano, C., Cundari, S., Rigamonti, L.M. (2005) Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. In Vivo, 19, 631-7.
18. Gimbel, J.S., Richards, P., Portenoy, R.K. (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology, 60, 927-34.
19. Hall, C.D., Snyder, C.R., Messenheimer, J.A., Wilkins, J.W., Robertson, W.T., Whaley, R.A., Robertson, K.R. (1991) Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction. Arch. Neurol., 48, 1273-4.
20. Harsing, L.G. Jr., Sershen, H., Toth, E., Hashim, A., Ramacci, M.T., Lajtha, A. (1992) Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur. J. Pharmacol, 218, 117-21.
21. Hart, A.M., Wiberg, M., Terenghi, G. (2002) Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L-carnitine treatment. Neurosci. Lett., 334, 181-5.
22. Hart, A.M., Wiberg, M., Youle, M., Terenghi, G. (2002) Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res., 145, 182-9.
23. Hart, A.M., Wilson, A.D., Montovani, C., Smith, C., Johnson, M., Terenghi, G., Youle, M. (2004) Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated aritiretroviral toxic neuropathy. AIDS, 18, 1549-60.
24. Imperato, A., Ramacci, M.T., Angelucci, L. (1989) Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci. Lett., 107, 251-5.
25. Inano, A., Sai, Y., Nikaido, H., Hasimoto, N., Asano, M., Tsuji, A., Tamai, I. (2003) Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos., 24, 357-65.
26. Ishii, T., Shimpo, Y., Matsuoka, Y., Kinoshita, K. (2000) Anti-apoptotic effect of acetyl-l-carnitine and I-carnitine in primary cultured neurons. Jpn. J. Pharmacol., 83, 119-24.
27. Jogl, G., Tong, L. (2003) Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport. Cell, 112, 113-22.
28. Kano, M., Kawakami, T., Hori, H., Hashimoto, Y., Tao, Y., Ishikawa, Y., Takenaka, T. (1999) Effects of ALCAR on the fast axoplasmic transport in cultured sensory neurons of streptozotocin-induced diabetic rats. Neurosci. Res., 33, 207-13.
29. Kido, Y., Tamai, I., Ohnari, A., Sai, Y., Kagami, T., Nezu, J., Nikaido, H., Hashimoto, N., Asano, M., Tsuji, A. (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J. Neurochem., 79, 959-69.
30. Koltzenburg, M. (1998) Painful neuropathies. Curr. Opin. Neurol., 11, 515-21.
31. Leijon, G., Boivie, J., Johansson, I. (1989) Central post-stroke pain--neurological symptoms and pain characteristics. Pain, 36, 13-25.
32. Lo Giudice, P., Careddu, A., Magni, G., Quagliata, T., Pacifici, L., Carminati, P. (2002) Autonomic neuropathy in streptozotocin diabetic rats: effect of acetyl-L-carnitine. Diabetes Res. Clin. Pract., 56, 173-80.
33. Lowitt, S., Malone, J.I., Salem, A.F., Korthals, J., Benford, S. (1995) Acetyl-L- carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism, 44, 677-80.
34. Marchand, F., Perretti, M., McMahon, S.B. (2005) Role of the immune system in chronic pain. Nat. Rev. Neurosci., 6, 521-32.
35. Moore, R.D., Wong, W.M., Keruly, J.C., McArthur, J.C. (2000) Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS, 14(3), 273-8.
36. Moyle, G. (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther., 22(8), 911-36
37. Moyle, G.J., Sadler, M. (1998) Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf., 19(6), 481-94
38. Nakamura, J., Koh, N., Sakakibara, F., Hamada, Y., Hara, T., Sasaki, H., Chaya, S., Komori, T., Nakashima, E., Naruse, K., Kato, K., Takeuchi, N., Kasuya, Y., Hotta, N. (1998) Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J. Pharmacol. Exp. Ther., 287, 897-902.
39. Pettegrew, J.W., Levine, J., McClure, R.J. (2000) Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry, 5, 616-32.
40. Piovesan, P., Pacifici, L., Taglialatela, G., Ramacci, M.T., Angelucci, L. (1994) Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res., 633, 77-82.
41. Pop-Busui, R., Marinescu, V., Van Huysen, C., Li, F., Sullivan, K., Greene, D.A., Larkin, D., Stevens, M.J. (2002) Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes, 51, 2619-28.
42. Rowbotham, M.C., Twilling, L., Davies, P.S., Reisner, L., Taylor, K., Mohr, D. (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med., 348, 1223-32.
43. Scarpini, E., Sacilotto, G., Baron, P., Cusini, M., Scarlato, G. (1997) Effect of acctyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J. Peripher. Nerv. Syst., 2, 250-2.
44. Schmader, K.E. (2002) Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain, 18(6), 350-4.
45. Schwab, M.E., Bartholdi, D. (1996) Degeneration and regeneration of axons in the lesioned spinal cord. Physiol., 76, 319-70.
46. Shug, A.L., Schmidt, M.J., Golden, G.T., Fariello, R.G. (1982) The distribution and role of carnitine in the mammalian brain. Life Sci., 31, 2869-74.
47. Sima, A.A., Calvari, M., Mehra, M., Amato, A. (2005) Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care, 28, 89-94.
48. Sima, A.A., Ristia, H., Merry, A., Kamijo, M., Lattimer, S.A., Stevens, M.J., Greene, D.A. (1996) Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J. Clin. Invest., 97, 1900-7.
49. Simpson, D.M., Tagliati, M. (1995) Nucleoside analogue-associated peripheral neuropathy in human imummodeficiency virus infection. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 9, 153-61.
50. Sindrup, SH., Jensen, T.S. (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 83, 389-400.
51. Stenager, E., Knudsen, L., Jensen, K. (1991) Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol. Scand., 84, 197-200.
52. Taglialatela, G., Navarra, D., Cruciani, R., Ramacci, M.T., Alema, G.S., Angelucci, L. (1994) Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp. Gerontol., 29, 55-66.
53. Waxman, S.G. (1999) The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain, 6, S133-40.
54. Wilson, A.D., Hart, A., Brannstrom, T., Wiberg, M., Terenghi, G. (2003) Primary sensory neuronal rescue with systemic acetyl-L-carnitine following peripheral axotomy. A dose-response analysis. Br. J. Plast. Surg., 56, 732-9.
55. Woolf, C.J., Mannion, R.J. (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 353, 1959-64
56. Woolf, C.J., Salter, M.W. (2000) Neuronal plasticity: increasing the gain in pain. Science, 9, 1765-9.